Search results
Results from the WOW.Com Content Network
In March 2017, ocrelizumab was approved in the United States for the treatment of primary progressive multiple sclerosis in adults. [22] [42] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. [42]
Statins: a family of cholesterol-lowering drugs, the statins, have shown anti-inflammatory effects in animal models of MS. [113] However, there is no evidence that statins are beneficial in the treatment of human MS patients, and concerns exist that, if ever shown to be effective, the high doses needed would prevent long-term use due to the ...
Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis.It is a humanized anti-CD20 monoclonal antibody. [8] It targets CD20 marker on B lymphocytes and is an immunosuppressive drug. [10]
Other tips include seeking 90-day prescription when possible, asking for the lowest price when deciding to pay for a medication, asking for generics (refer to "Generics versus Brand-name Products" for more details regarding generic drugs vs. brand-name drugs), comparing insurance plans and talking to your doctor about costs in order to find ...
The graver course is one form of malignant multiple sclerosis, with patients reaching a significant level of disability in less than five years from their first symptoms, often in a matter of months. [2] Sometimes Marburg MS is considered a synonym for tumefactive MS, [3] but not for all authors. [citation needed]
Medication therapy management, generally called medicine use review in the United Kingdom, is a service provided typically by pharmacists, medical affairs, and RWE scientists that aims to improve outcomes by helping people to better understand their health conditions and the medications used to manage them. [1]
Siponimod is indicated for the treatment of secondary progressive multiple sclerosis, which is the progressive neurological decline of multiple sclerosis that happens independent of acute relapses. [1] In active secondary progressive multiple sclerosis, siponimod decreases the risk of disability and multiple sclerosis relapses. [1]
Multiple sclerosis (MS) is an autoimmune disease resulting in damage to the insulating covers of nerve cells in the brain and spinal cord. [3] As a demyelinating disease , MS disrupts the nervous system's ability to transmit signals , resulting in a range of signs and symptoms , including physical, mental , and sometimes psychiatric problems.